Trial Number
354-23
Participant Age Range
12 years to 17 years
Participant Gender
Any
Enrolling Participants
Yes
Overview
“A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age with Chronic Migraine – the REBUILD-2 Study”
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Provider
Jasmin M Dao, MD
Neurology - Pediatric, Pediatric Neurology
Jasmin M Dao, MD
Neurology - Pediatric, Pediatric Neurology
